
    
      This is a multiple-center open-label clinical trial to study the efficacy and safety of
      voriconazole for treating invasive pulmonary aspergillosis secondary to COPD in Chinese
      patients.The primary endpoint is treatment success rate as defined by improvement of symptoms
      related to invasive pulmonary asperillosis, secondary endpoints include the mortality, the
      eradication of sputum asperillus and profile of adverse reactions following intravenous
      instillation of voriconazole.
    
  